Trial Profile
Investigation of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Oral Doses of 75 mg Molidustat in Male and Female Subjects With Renal Impairment Requiring Hemo- or Peritoneal Dialysis Compared to Age- and Weight-matched Healthy Subjects in a Single-center, Non-controlled, Non-blinded Study With Group Stratification
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2021
Price :
$35
*
At a glance
- Drugs Molidustat (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors Bayer
- 14 Jun 2016 Status changed from active, no longer recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2020.
- 26 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016, as reported by ClinicalTrials.gov.